We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
- Authors
Ferrari, Michel D.; Zuurbier, Karin W. M.; Barash, Steve; Ning, Xiaoping; Cohen, Joshua M.
- Abstract
The article presents the discussion on Fremanezumab in individuals with chronic migraine showing inadequate response to onabotulinumtoxin A and topiramate or valproic acid. Topics include Fremanezumab, a humanized monoclonal antibody (IgG2Δa) selectively target calcitonin gene-related peptide; and treatment-by-subgroup interactions being assessed using an analysis of covariance model for the efficacy outcomes.
- Subjects
THERAPEUTIC use of monoclonal antibodies; BOTULINUM toxin; DRUG efficacy; STATISTICS; MIGRAINE; CHRONIC diseases; MONOCLONAL antibodies; TREATMENT effectiveness; DATA analysis; TOPIRAMATE; VALPROIC acid
- Publication
Headache: The Journal of Head & Face Pain, 2022, Vol 62, Issue 4, p530
- ISSN
0017-8748
- Publication type
Article
- DOI
10.1111/head.14294